| Oct 16 |
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
|
| Oct 9 |
Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...
|
| Sep 27 |
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
|
| Sep 16 |
Lexicon Pharmaceuticals announces departure of President, COO Jeff Wade
|
| Sep 16 |
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
|
| Sep 10 |
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
|
| Sep 3 |
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
|
| Sep 3 |
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
|
| Sep 2 |
Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?
|
| Aug 28 |
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
